A Phase 2 interventional study of NT 201 and Placebo in Essential Tremor of the Upper Limb, sponsored by Merz Pharmaceuticals GmbH. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 2, Interventional, and Treatment
Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor:…PubMed 42931526 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.
Among the 146 studies in Essential Tremor with a site in United States, this one is the 27th largest by enrollment of the 104 interventional ones that give a count, is one of 12 that started in 2021, is one of 21 in phase 2, and was the 103rd registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:
Encora, Inc. · Sites in United States
Ages 18+
AbbVie · Sites in United States, Canada
Ages 18–85
University of California, Los Angeles · Sites in United States
Ages 18–90
CND Life Sciences · Sites in United States
Ages 50–85
Boston University Charles River Campus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 3 5 · Phase 4 5
First in 2000; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 30 across the 104 interventional studies, 81 across the 41 observational. Of the 86 that completed or were terminated, 39 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merz Pharmaceuticals GmbH, one of the names counted as Merz Pharma. Under that name alone:
Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.
Merz Pharma has 2 studies filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
13 of the studies in Essential Tremor with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03778060Mayo ClinicLong-Term Transcutaneous Stimulation and Essential Tremor: A PET Study | 2026-12 |
| NCT07599592University of California, Los AngelesOpen Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor | 2026-12-31 |
| NCT07428447CND Life SciencesAnalysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | 2027-02 |
| NCT04286308Massachusetts General HospitalCortical-Basal Ganglia Speech Networks | 2027-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 146 studies in Essential Tremor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a single treatment with NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the motor-dominant arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
The following treatment cycle will investigate the safety and tolerability of two-sided treatment with NT 201 (botulinum toxin) (Open Label Bilateral Period). All participants will receive NT 201 treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Score of ≥ 2 (at least 1 cm tremor amplitude) in at least two out of three maneuvers of test item 4 (upper limb tremor) of the TETRAS performances scale confirmed by an independent TETRAS expert by means of video assessment.
Exclusion Criteria:
Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of both upper limbs.
Drug: NT 201
Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the motor-dominant upper limb. Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of both upper limbs.
Drug: NT 201 · Drug: Placebo
Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Also known as: Incobotulinumtoxin A, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist
TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.
Time frame: Baseline up to Week 6
Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.
Time frame: Baseline up to Week 6
Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor \[items 2-9\]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.
Time frame: Baseline up to Week 6
Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.
Time frame: Baseline up to Week 6
Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6
The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.
Time frame: Week 6
Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6
The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.
Time frame: Week 6
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score
TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.
Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.
Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length =12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.
Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.
Time frame: Baseline of Cycle 2 up to Week 6 (Cycle length = 12 weeks)
Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).
Time frame: Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study(Week 36)
Subjects were recruited at 14 investigational sites in the United States, Poland and Canada.
| Milestone | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Bilateral Treatment Period: NT 201 |
|---|---|---|---|
| Started | 51 | 27 | 0 |
| Completed | 48 | 26 | 0 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
| Milestone | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Bilateral Treatment Period: NT 201 |
|---|---|---|---|
| Started | 0 | 0 | 72 |
| Completed | 0 | 0 | 71 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
TremorTek kinematic analytic investigational device is combination of computer software and wearable movement sensors that allows to collect motion data when placed on individual's arm to quantify tremor in various muscle groups that impact shoulder, elbow, wrist. This assessment system was used to measure maximum angular tremor amplitude at wrist of injected limb (unit: degrees). Angular tremor amplitude was measure of tremor severity. Reduction of maximum angular tremor amplitude at wrist of injected limb represented tremor improvement.
| degrees of arc | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist | -0.25 ± 0.140 | -0.46 ± 0.180 |
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 (including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.
| score on a scale | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Change From Baseline to Week 6 in the Essential Tremor Rating Assessment Scale (TETRAS) Performance Dominant Upper Limb (UL) Score as Assessed by Investigator | -2.3 ± 2.60 | -0.9 ± 1.56 |
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items (on UL tremor \[items 2-9\]). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.
| score on a scale | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Change From Baseline to Week 6 in the TETRAS Activities of Daily Living (ADL) UL Score | -3.7 ± 5.00 | -3.8 ± 4.46 |
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.
| score on a scale | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Change From Baseline to Week 6 in TETRAS ADL Functional Impact Score | -1.2 ± 1.87 | -1.3 ± 1.83 |
The GICS was used to evaluate overall clinical impression of change after treatment by the subject. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.
| score on a scale | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Subject's Global Impression of Change Scale (GICS) Score of Motor-dominant UL at Week 6 | 0.9 ± 1.27 | 0.8 ± 1.14 |
The GICS was used to evaluate the overall clinical impression of change after treatment by the investigator. The response option was a common 9-point Likert scale ranged from -4 to +4, with the following values: +4 (very much improved); +3 (much improved); +2 (improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (worse); -3 (much worse); -4 (very much worse). A higher score indicated improvements.
| score on a scale | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo |
|---|---|---|
| Unilateral Treatment Period: Investigator's GICS Score of Motor-dominant UL at Week 6 | 1.2 ± 1.36 | 0.8 ± 1.03 |
TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. The TETRAS Performance dominant UL score included TETRAS Performance items 4 ((including subitems a, b, c for 3 manoeuvres), 6 to 8 of dominant UL. Each individual item score ranged from 0 to 4. The performance dominant UL score ranged from 0 to 24. Higher scores indicated more severe tremor.
| score on a scale | Bilateral Treatment Period: NT 201 |
|---|---|
| Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Dominant UL Score | -2.8 ± 2.62 |
The TETRAS was a validated clinical scale for the assessment of essential tremor severity. The TETRAS performance subscale was utilized by the qualified investigators to assess the tremor severity. TETRAS performance subscale consisted of 9 items: head, face, and voice tremor (items 1-3), UL tremor of right and left UL (item 4) in three tasks (forward outstretched postural tremor, lateral "wing-beating" postural tremor, kinetic tremor), Archimedes spirals with both hands, handwriting with motor-dominant hand, and dot approximation task with both hands (items 6-8), and lower limb tremor and standing tremor (items 5 and 9). Each item was rated from 0 (no tremor) to 4 (severe tremor) with overall performance score of 0 to 64, calculated as the sum of subscale items. Higher scores indicated greater tremor severity.
| score on a scale | Bilateral Treatment Period: NT 201 |
|---|---|
| Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS Performance Subscale Score | -5.6 ± 5.14 |
TETRAS ADL subscale was another component of TETRAS. ADL subscale of TETRAS was completed by study subjects through an interview procedure to assess impact of tremor on activities of daily living. TETRAS ADL UL score was the sum of eight ADL items on UL tremor (items 2-9). Items were rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL UL score ranged from 0 to 32. Higher scores indicated greater tremor severity.
| score on a scale | Bilateral Treatment Period: NT 201 |
|---|---|
| Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL UL Score | -4.4 ± 4.07 |
TETRAS ADL Functional Impact score was the sum of the following three ADL items: occupational impairment (item 10), overall disability (item 11), and social impact (item 12) of ET. The items are rated on a 5-point response scale each ranged from 0 (normal status/impact) to 4 (severe status/impact). The ADL Functional Impact score ranged from 0 to 12. Higher scores indicated greater tremor severity.
| score on a scale | Bilateral Treatment Period: NT 201 |
|---|---|
| Bilateral Treatment Period: Change From Cycle 2 Baseline to Week 6 in TETRAS ADL Functional Impact Score | -1.4 ± 1.42 |
An adverse event (AE) is any untoward medical occurrence in subject administered pharmaceutical product. TEAEs of unilateral treatment period (Cycle 1) = AEs from first injection up to injection in the bilateral treatment period (Week 24). TEAEs of bilateral treatment period (Cycle 2) = AEs from injection in bilateral treatment period up to end of study (Week 36).
| percentage of subjects | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Bilateral Treatment Period: NT 201 |
|---|---|---|---|
| Percentage of Subjects With At-least One Treatment Related Treatment-emergent Adverse Events (TEAEs) | 30.0 | 3.7 | 30.6 |
Collected over Unilateral Treatment Period: From first injection in unilateral treatment period up to re-injection in Bilateral Treatment Period (Week 24); Bilateral Treatment Period: From re-injection in Bilateral Treatment Period at Week 24 up to end of study (Week 36). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Unilateral Treatment Period: NT 201 | 0/50 (0%) | 3/50 (6%) | 29/50 (58%) |
| Unilateral Treatment Period: Placebo | 0/27 (0%) | 2/27 (7.4%) | 5/27 (18.5%) |
| Bilateral Treatment Period: NT 201 | 0/72 (0%) | 2/72 (2.8%) | 29/72 (40.3%) |
| Event | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Bilateral Treatment Period: NT 201 |
|---|---|---|---|
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 1/27 | 0/72 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/50 | 1/27 | 0/72 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/50 | 1/27 | 0/72 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 0/27 | 0/72 |
| Condition aggravatedGeneral disorders | 1/50 | 0/27 | 0/72 |
| CholelithiasisHepatobiliary disorders | 1/50 | 0/27 | 0/72 |
| PneumoniaInfections and infestations | 1/50 | 0/27 | 0/72 |
| Skull fractureInjury, poisoning and procedural complications | 0/50 | 0/27 | 1/72 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/50 | 0/27 | 1/72 |
| Atrial fibrillationCardiac disorders | 0/50 | 0/27 | 1/72 |
| Event | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Bilateral Treatment Period: NT 201 |
|---|---|---|---|
| Muscular weaknessMusculoskeletal and connective tissue disorders | 12/50 | 0/27 | 17/72 |
| FallInjury, poisoning and procedural complications | 1/50 | 2/27 | 3/72 |
| HypertensionVascular disorders | 3/50 | 0/27 | 0/72 |
| Back painMusculoskeletal and connective tissue disorders | 3/50 | 0/27 | 0/72 |
| Injection site haemorrhageGeneral disorders | 2/50 | 1/27 | 0/72 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/50 | 0/27 | 1/72 |
| Herpes zosterInfections and infestations | 2/50 | 0/27 | 0/72 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 1/27 | 0/72 |
| FatigueGeneral disorders | 0/50 | 1/27 | 0/72 |
| Influenza like illnessGeneral disorders | 0/50 | 1/27 | 0/72 |
Randomized population.
| Age, Customized(Participants) | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Total |
|---|---|---|---|
| 18-64 years | 18 | 11 | 29 |
| 65-84 years | 32 | 15 | 47 |
| >= 85 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Total |
|---|---|---|---|
| Female | 25 | 12 | 37 |
| Male | 26 | 15 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 50 | 26 | 76 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Unilateral Treatment Period: NT 201 | Unilateral Treatment Period: Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 49 | 26 | 75 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Apr 2023, 26 months.
Results were first posted in Apr 2026, 3 years after primary completion. A results delay was requested in Apr 2024.
Of 20 phase 2 interventional studies under Essential Tremor, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor:…PubMed 42931526 ↗
Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, Bagretsova A, Klein G, Geister TL, Pulte I, Jog M. IncobotulinumtoxinA for Upper Limb Essential Tremor:…PubMed 42931526 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: incobotulinumtoxinA